Tech Company Financing Transactions
DxNA Funding Round
Private investors participated in a $2.5 million capital raise for DxNA. This venture round was announced on 11/22/2013.
Transaction Overview
Company Name
Announced On
11/22/2013
Transaction Type
Venture Equity
Amount
$2,500,000
Round
Undisclosed
Investors
Proceeds Purpose
DxNA will use the funds to move two of its products through the US Food and Drug Administration regulatory process. The investment will also be used to initiate the regulatory process for the company's PCR-based MRSA assay.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
180 N 300 E
St. George, UT 84770
USA
St. George, UT 84770
USA
Phone
Website
Email Address
Not Recorded
Overview
DxNA develops integrated systems and tests for rapid real-time PCR molecular diagnostics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Taus
Chief Financial Officer
Roger Jensen
Chief Operating Officer
Ernest Sumsion
VP - R & D
Michael Wood
Browse more venture capital transactions:
Prev: 11/22/2013: BIME Analytics venture capital transaction
Next: 11/22/2013: TapCommerce venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs